Jurriaan Brouwer‐Visser
Regeneron (United States)(US)Progenics Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
CAR-T cell therapy research, Lymphoma Diagnosis and Treatment, Sarcoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial(2018)218 cited
- → IGF2 signaling and regulation in cancer(2015)120 cited
- → Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer(2010)95 cited
- → Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma(2024)69 cited
- → CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models(2022)49 cited
- → Immune contexture of paediatric cancers(2022)48 cited